

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/806,462	03/22/2002	Koji Kigawa	084335/0134	4495
23533	7590 09/15/2003			
STEPHEN B MAEBIUS FOLEY AND LARDNER 3000 K STREET N W SUITE 500			EXAMINER	
			STRZELECKA	STRZELECKA, TERESA E
WASHINGTO	ON, DC 20007-5109		ART UNIT	PAPER NUMBER
			1637	1
			DATE MAILED: 09/15/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

./		Application No.	Applicant(s)			
Office Action Summary		09/806,462	KIGAWA ET AL.			
		Examiner	Art Unit			
		Teresa E Strzelecka	1637			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status		07.0000				
1)⊠	Responsive to communication(s) filed on <u>May</u>					
2a)□	,—	is action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠ Claim(s) <u>1-21</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)☐ Claim(s) is/are rejected.						
7)☐ Claim(s) is/are objected to.						
·	Claim(s) <u>1-21</u> are subject to restriction and/or e	election requirement.				
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) 🗌 T	he proposed drawing correction filed on	is: a)☐ approved b)☐ disappro	ved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	r (PTO-413) Paper No(s) Patent Application (PTO-152)			

Application/Control Number: 09/806,462

Art Unit: 1637

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-9, 13, 14, 17, drawn to a method of preparing a RecA-like recombinase /single stranded nucleic acid probe complex.

Group II, claim(s) 11, 12, 18-20, drawn to a method for targeting, enriching, detecting and/or isolating double stranded nucleic acid by contacting a RecA-like recombinase /single stranded nucleic acid probe complex with a sample containing the double stranded nucleic acid.

Group III, claim(s) 15, drawn to a method of detecting a double stranded nucleic acid in a fixed sample by in situ hybridization using a RecA-like recombinase/single stranded nucleic acid probe complex.

Group IV, claim(s) 16, drawn to a method of detecting a double stranded nucleic acid in a living cell sample by in vivo gene targeting using a RecA-like recombinase /single stranded nucleic acid probe complex and to a kit comprising RecA-like recombinase /single stranded nucleic acid probe complex.

Group V, claim(s) 10 and 21, drawn to a kit for preparing RecA-like recombinase /single stranded nucleic acid probe complex, the kit comprising RecA-like recombinase and nonhydrolyzable nucleotide cofactor, and a kit for targeting, enriching, detecting and/or isolating double stranded nucleic acid in a sample, the kit comprising RecA-like recombinase /single stranded nucleic acid probe complex.

2. The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Radding et al. (U. S. Patent No. 4,888,274) teaches complexes between RecA protein and single stranded nucleic acids which may be used for enrichment of double-stranded DNA and other reactions (Abstract).

Art Unit: 1637

- 3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Teresa E Strzelecka whose telephone number is (703) 306-5877. The examiner can normally be reached on M-F (8:30-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (703) 308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

TS

September 11, 2003

75

JEFFREY FREDMAN PRIMARY EXAMINER